The latest price target for Sonnet BioTherapeutics (NASDAQ:SONN) was reported by Chardan Capital on December 20, 2024. The analyst firm set a price target for $20.00 expecting SONN to rise to within 12 months (a possible 1233.33% upside). 5 analyst firms have reported ratings in the last year.

The latest analyst rating for Sonnet BioTherapeutics (NASDAQ:SONN) was provided by Chardan Capital, and Sonnet BioTherapeutics maintained their buy rating.

There is no last upgrade for Sonnet BioTherapeutics

There is no last downgrade for Sonnet BioTherapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sonnet BioTherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sonnet BioTherapeutics was filed on December 20, 2024 so you should expect the next rating to be made available sometime around December 20, 2025.

While ratings are subjective and will change, the latest Sonnet BioTherapeutics (SONN) rating was a maintained with a price target of $30.00 to $20.00. The current price Sonnet BioTherapeutics (SONN) is trading at is $1.50, which is out of the analyst’s predicted range.